Messages from Japan policy for viral hepatitis

Area of Science:

• Hepatology and Viral Hepatitis Research
• Public Health Policy and Implementation
• Health Economics and Healthcare Management

Background:

• Japan has substantial chronic hepatitis B (HBV) and hepatitis C (HCV) burdens, with millions affected.
• Hepatocellular carcinoma (HCC) mortality peaked around 2002 and has since declined.
• National action plans and guidelines aim to control viral hepatitis, with government-subsidized screening and treatment.

Discussion:

• Government initiatives provide free or low-cost screening for HBV and HCV for individuals over 40.
• Special programs cover drug costs and examinations for chronic hepatitis B and C patients.
• Expanded coverage for HBV/HCV-induced liver cancer and decompensated cirrhosis began in December 2018.

Key Insights:

• Despite progress, significant gaps persist in the viral hepatitis care cascade, including diagnosis and treatment.
• Japanese healthcare offers advantages for viral liver disease patients compared to other Western Pacific Region countries.
• The nation's established hepatitis control measures position it to lead regional action plans.

Outlook:

• Continued efforts are needed to bridge existing gaps in the hepatitis care cascade.
• Japan's experience can inform and guide other countries in developing effective hepatitis action plans.
• Further integration of healthcare services and patient support is crucial for comprehensive hepatitis management.